BMS to Present P-III Trial (CheckMate -816) Results of Opdivo (nivolumab) for Resectable Non-Small Cell Lung Cancer at ELCC 2023
- The 3yr. follow-up results from the P-III trial evaluating Opdivo + CT vs CT alone in 358 patients with resectable stage IB to IIIA NSCLC, regardless of PD-L1 expression
- The results showed sustained clinical benefits, 32% reduction in risk of disease recurrence, progression, or death with a median follow-up of 41.4mos., 3yr. EFS rate of 57% vs 43%, TTDM continued to favor Opdivo with CT with 3yr. landmark TTDM rates of 71% vs. 50%
- OS remained immature, 78% vs 64% were alive @3yrs. The combination therapy continues to demonstrate improved EFS benefits in the explanatory analysis @3yrs. & safety profile was consistent with the primary analysis with no new safety signals, grade 3-4 treatment-related & surgery-related AEs (36% & 11% vs 38% & 15%), respectively
Ref: neoadjuvant | Image: neoadjuvant
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.